Alzheimer’s Disease is the most common cause of dementia. Dementia describing a specific set of symptoms such as memory loss, difficulties with problem-solving, language or simply thinking. As the disease progresses, proteins build up in the brain to form structures called ‘plaques’. Eventually there is a break between the nerve cells resulting the death of the cells and a loss of brain tissue. ending in a lack of motor skills. Although progression can vary, typically after diagnosis life expectancy is around three to nine years. Fewer than 3% of people live more than fourteen years.
Management
Medications, psychological intervention and care-giving are all available to AD patients. there are currently 5 different medications on offer for AD each have different results and side affects.
A second groundbreaking drug for Alzheimer's disease has been rejected for widespread use by the NHS in England; according to the drugs spending watchdog, the drug known as Donanemab does not offer sufficient value for money.
Dhivya Venkat, CEO & Co-Founder of Esya Inc., discusses the urgent need for integrating innovative diagnostics and therapies into the NHS in order to improve dementia care and diagnosis.
According to the World Health Organization (WHO), dementia is the third leading cause of mortality in Europe and the seventh globally, with a societal cost in Europe estimated to be €392bn in 2019. By 2025, 9.1 million people will be living with dementia in the European Union, rising to 14.3 million in 2050. We discuss dementia care provision with Alzheimer Europe.
Cambridge Vision Technology utilises AI-based technology to detect Alzheimer’s disease early on by using ocular biomarkers. They emphasise the importance of early detection of dementia to improve clinical outcomes for disease therapies and to maximise the economic and societal impact of this innovative new technology.
Neurological diseases are the foremost cause of ill health and disability worldwide. Open Access Government offers an overview of the prevalence of these conditions.
In June, Alzheimer's and brain awareness month, Mayo Clinic researchers have identified unique molecular signatures of blood-brain barrier dysfunction in Alzheimer's disease.
Researchers at Queen Mary University of London have made a significant breakthrough in the early prediction of dementia, developing a new method that can predict the disease with over 80% accuracy up to nine years before a clinical diagnosis.
Researchers have found a new method to distinguish between Dementia with Lewy Bodies (DLB) and Alzheimer's Disease (AD) using vocal emotional expressions.
A recent study led by the Molecular and Cellular Neurobiotechnology group at the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona...
As the population ages, the economic toll of dementia on the UK is projected to skyrocket, reaching £91 billion a year by 2040, according to a study conducted for the Alzheimer’s Society.
Researchers have found evidence suggesting that lifestyle factors may play a pivotal role in mitigating the risk of Alzheimer's disease, even among individuals carrying the ApoE4 gene variant.
Researchers from the University of Technology Sydney (UTS), UNSW Sydney, and the Agency for Science, Technology and Research in Singapore have found a link between air pollution and Alzheimer's disease.
